Evoworks Bio
Cambridge-based biotechnology company (founded 2023) developing a biomimetic bioreactor platform that enables direct lab-to-production scaling with integrated measurements, aiming to shorten development timelines and enable cGMP clinical production while supporting a range of bioproducts.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Scalable bioreactor platform (lab-to-clinic)
A biomimetic bioreactor platform that provides integrated measurement and enables direct scale-up from lab experiments to ~10 L in-lab volumes and onward to cGMP clinical production.
Scalable bioreactor platform (lab-to-clinic)
A biomimetic bioreactor platform that provides integrated measurement and enables direct scale-up from lab experiments to ~10 L in-lab volumes and onward to cGMP clinical production.
Services
Collaborative development engagements to adapt and scale biological processes using the company's platform within customer labs.
Support to transition processes to cGMP-compliant production and integration with CDMO workflows for clinical trial supply.
Collaborative development engagements to adapt and scale biological processes using the company's platform within customer labs.
Support to transition processes to cGMP-compliant production and integration with CDMO workflows for clinical trial supply.
Expertise Areas
- Bioprocess scale-up
- Bioreactor design and engineering
- Process development for fermentation and cell culture
- Process analytical technology (PAT) integration
Key Technologies
- Bioreactor scale-up platforms
- Process analytical technology (PAT)
- Real-time bioprocess sensors
- cGMP manufacturing systems
News & Updates
Presentation to a group of government and production experts introduced via IBx Connect, discussing the platform's ability to address bioproduction challenges for biotech and defense.
Acceptance into an accelerator program focused on 'Tough Tech' leadership and founder education.
Selected as a finalist in the Sloane Healthcare Innovation Prize and presented at MIT Media Lab.
Selected for the 2025 BioTools Innovator cohort with a focus on government engagement via a BARDA Vanguard specialty track.
Selected for the 2025 BioTools Innovator cohort with emphasis on government engagement.
Named a finalist in the 23rd Sloane Healthcare Innovation Prize and presented at MIT Media Lab.
Presentation to a group of government and production experts introduced via IBx Connect, discussing the platform's ability to address bioproduction challenges for biotech and defense.
Acceptance into an accelerator program focused on 'Tough Tech' leadership and founder education.
Selected as a finalist in the Sloane Healthcare Innovation Prize and presented at MIT Media Lab.
Selected for the 2025 BioTools Innovator cohort with a focus on government engagement via a BARDA Vanguard specialty track.
Selected for the 2025 BioTools Innovator cohort with emphasis on government engagement.
Named a finalist in the 23rd Sloane Healthcare Innovation Prize and presented at MIT Media Lab.